# Protocol Review and Monitoring System

> **NIH NIH P30** · EMORY UNIVERSITY · 2021 · $111,975

## Abstract

PROTOCOL REVIEW AND MONITORING SYSTEM
PROJECT SUMMARY/ ABSTRACT
The Protocol Review and Monitoring System (PRMS), administered by Winship’s Clinical and Translational
Review Committee (CTRC), is responsible for the review and approval of all cancer clinical trials proposed by
Winship members for scientific quality and merit. The CTRC is charged with the responsibility to prioritize,
monitor, and terminate clinical trials based on ongoing scientific validity, feasibility, overall progress, and patient
accrual. CTRC’s overarching goal is to support and facilitate the conduct of Winship’s clinical cancer research
efforts. To fulfil this goal, CTRC addresses the following set of objectives using clearly-defined criteria and
mechanisms to: (1) review new clinical research proposals for scientific rationale, appropriate design, and
feasibility; (2) prioritize clinical research proposals using uniform and objective metrics in consultation with
Winship’s cancer disease-site working groups and with Winship’s research programs to ensure alignment with
Winship’s overall strategic objectives; (3) review and monitor the progress of active clinical studies for accrual
and scientific validity, and to terminate protocols which are not meeting accrual targets and/or where new
scientific evidence renders the study irrelevant; (4) determine and assign level of potential risk to patients enrolled
on study that will inform the rigor and frequency of review by Winship’s Data Safety Monitoring Committee
(DSMC); and (5) provide a platform for educating the next generation of clinical researchers on the best practices
in the design and conduct of cancer clinical trials. The CTRC functions as a distinct, independent body from the
Winship Clinical Trials Office (CTO) and the DSMC. Significant changes instituted to enhance the function of the
CTRC in response to suggestions emanating from the last CCSG competitive renewal include: (1) enactment of
review guidelines to assess the ability of new studies to meet accrual targets, with special attention to potential
eligibility conflict with ongoing clinical trials; (2) adding a requirement that new study proposals address scientific
questions relevant to Winship’s overall mission and objectives of its research programs; (3) adding a requirement
for institutional (investigator-initiated) proposals to undergo biostatistics review prior to submission for CTRC
review and to include a co-investigator from Winship’s Biostatistics and Bioinformatics Shared Resource
(BBISR); (4) requiring a risk level determination at the time of scientific review for all treatment trials; (5) instituting
a regular biennial survey of Winship members to obtain feedback on CTRC function and value added to
Winship’s clinical research activities; and (6) recognizing outstanding CTRC members (excluding co-chairs)
based on specific metrics including meeting attendance and protocol review.

## Key facts

- **NIH application ID:** 10146989
- **Project number:** 5P30CA138292-13
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Timothy Steven Olson
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $111,975
- **Award type:** 5
- **Project period:** 2009-04-07 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10146989

## Citation

> US National Institutes of Health, RePORTER application 10146989, Protocol Review and Monitoring System (5P30CA138292-13). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10146989. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*